Agaricus Blazei Murill in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Dietary Supplement: Intake of 60 ml placebo daily in addition to chemotherapyDietary Supplement: Intake of 60 ml agaricus daily in addition to chemotherapy
- Registration Number
- NCT00970021
- Lead Sponsor
- Ullevaal University Hospital
- Brief Summary
Extract from the mushroom Agaricus blazei Murill har been shown to have strong immunomodulating properties both in cell cultures, animal models and in humans. Furthermore antitumor properties have been shown in animal models, among them in mice with multiple myeloma. The investigators now want to investigate the effect of Agaricus as supplementary treatment in addition to chemotherapy in patients with multiple myeloma.
- Detailed Description
Patients who are scheduled to undergo high dose chemotherapy for multiple myeloma will receive in addition in a double blinded manner 60 ml of agaricus extract or placebo once daily from the start of stem cell mobilizing therapy until one week after the end of aplasia after high dose melphalan.
Primary endpoints will be cytokine levels of degree of activation of tumor supressor genes before and after start of the investigational product.
Secondary endpoints will be treatment response and quality of life.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
- Patients scheduled to undergo high dose chemotherapy with autologous stem cell support for multiple myeloma
- None
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Water with artificial colour Intake of 60 ml placebo daily in addition to chemotherapy Placebo Extract of agaricus blazei Murill Intake of 60 ml agaricus daily in addition to chemotherapy Agaricus blazei Murill
- Primary Outcome Measures
Name Time Method Cytokine levels in serum 7 weeks
- Secondary Outcome Measures
Name Time Method Quality of Life 4 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Department of hematology, Oslo University Hospital, Ullevaal
🇳🇴Oslo, Norway